Liraglutide 3 mg (NN8022)

:Obesity
:Filed for registration

A once-daily human GLP-1 analogue for use as adjuvant to lifestyle changes intended to offer weight loss for people with severe obesity, including those at particular risk of developing diabetes. Under regulatory review in the US and the EU.

Company announcements
Saxenda┬« for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee (11 Sep 2014)
FDA posts briefing materials prior to Advisory Committee meeting for Saxenda┬« for the treatment of obesity (09 Sep 2014)
FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity (20 May 2014)
Read more company announcements

Press releases
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo (21 Jun 2014)
New phase 3a liraglutide 3 mg data showed positive impact on cardiovascular risk markers and fewer people progressing to prediabetes compared with placebo in adults with obesity (21 Jun 2014)
Phase 3a data showed liraglutide 3 mg demonstrated significantly greater weight loss compared to placebo in adults with obesity and type 2 diabetes (14 Jun 2014)
Read more press releases

Scientific abstracts
Diabetes (2007)
Diabetes Obesity and Metabolism (2008)
Diabetes Obesity and Metabolism (2008)
Read more scientific abstracts

You can search for more clinical trials on http://clinicaltrials.gov
  •